Department of Thoracic Surgery, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA.
Ann Thorac Surg. 2011 Aug;92(2):428-32; discussion 433. doi: 10.1016/j.athoracsur.2011.02.052. Epub 2011 May 18.
The 18 F-fluorodeoxyglucose-positron emission tomography (FDG-PET) is used to evaluate suspicious pulmonary lesions due to its diagnostic accuracy. The southeastern United States has a high prevalence of infectious granulomatous lung disease, and the accuracy of FDG-PET may be reduced in this population. We examined the diagnostic accuracy of FDG-PET in patients with known or suspected non-small cell lung cancer treated at our institution.
A total of 279 patients, identified through our prospective database, underwent an operation for known or suspected lung cancer. Preoperative FDG-PET in 211 eligible patients was defined by standardized uptake value greater than 2.5 or by description ("moderate" or "intense") as avid. Sensitivity, specificity, positive and negative predictive values, likelihood ratios, and decision diagrams were calculated for FDG-PET in all patients and in patients with indeterminate nodules.
In all eligible patients (n=211), sensitivity and specificity of FDG-PET were 92% and 40%, respectively. Positive and negative predictive values were 86% and 55%. Overall FDG-PET accuracy to diagnose lung cancer was 81%. Preoperative positive likelihood ratio for FDG-PET diagnosis of lung cancer in this population was 1.5 compared with previously published values of 7.1. In 113 indeterminate lesions, 65% had lung cancer and the sensitivity and specificity were 89% and 40%, respectively. Twenty-four benign nodules (60%) had false positive FDG-PET scans. Twenty-two of 43 benign nodules (51%) were granulomas.
In a region with endemic granulomatous diseases, the specificity of FDG-PET for diagnosis of lung cancer was 40%. Clinical decisions and future clinical predictive models for lung cancer must accommodate regional variation of FDG-PET scan results.
18F-氟代脱氧葡萄糖正电子发射断层扫描(FDG-PET)用于评估可疑的肺部病变,因其具有较高的诊断准确性。美国东南部地区传染性肉芽肿性肺部疾病的发病率较高,因此该地区 FDG-PET 的准确性可能会降低。我们研究了本机构治疗的已知或疑似非小细胞肺癌患者中 FDG-PET 的诊断准确性。
通过我们的前瞻性数据库共确定了 279 名接受手术治疗的已知或疑似肺癌患者。211 名符合条件的患者进行了术前 FDG-PET 检查,标准摄取值大于 2.5 或描述为“中度”或“强烈”为阳性。在所有患者和不确定结节患者中计算了 FDG-PET 的敏感性、特异性、阳性和阴性预测值、似然比和决策图。
在所有合格患者(n=211)中,FDG-PET 的敏感性和特异性分别为 92%和 40%。阳性和阴性预测值分别为 86%和 55%。总体而言,FDG-PET 诊断肺癌的准确率为 81%。在该人群中,FDG-PET 术前诊断肺癌的阳性似然比为 1.5,而先前报道的数值为 7.1。在 113 个不确定病变中,有 65%为肺癌,敏感性和特异性分别为 89%和 40%。24 个良性结节(60%)出现了假阳性 FDG-PET 扫描。43 个良性结节中有 22 个(51%)为肉芽肿。
在存在地方性肉芽肿性疾病的地区,FDG-PET 诊断肺癌的特异性为 40%。肺癌的临床决策和未来的临床预测模型必须适应 FDG-PET 扫描结果的区域差异。